Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.80 USD
Change Today +0.1499 / 4.11%
Volume 5.1M
As of 3:38 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

mannkind corp (MNKD) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/10/15 - $7.88
52 Week Low
08/26/15 - $3.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MANNKIND CORP (MNKD)

mannkind corp (MNKD) Details

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. Its lead product is AFREZZA inhalation powder, an insulin to control high blood sugar in adult patients with type 1 and type 2 diabetes. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.

287 Employees
Last Reported Date: 03/2/15
Founded in 1991

mannkind corp (MNKD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $748.8K
Founder and Executive Chairman
Total Annual Compensation: $858.6K
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $466.0K
Chief Operating Officer and Corporate Vice Pr...
Total Annual Compensation: $479.2K
Corporate Vice President, General Counsel and...
Total Annual Compensation: $409.2K
Compensation as of Fiscal Year 2014.

mannkind corp (MNKD) Key Developments

MannKind Corp. Announces Addition of Raymond Urbanski as its Chief Medical Officer

MannKind Corp. announced the appointment of Dr. Raymond Urbanski as its Chief Medical Officer. As Chief Medical Officer, Dr. Urbanski will lead MannKind's overall drug development activities and will be a member of the Executive Leadership Team. Dr. Urbanski has more than 25 years of research, clinical and pharmaceutical industry experience developing numerous new drugs and indications across oncology, rheumatology, cardiology, endocrinology, and immunology. He has held CMO roles at Mylan and Metabolix. Previously he was Vice President at Pfizer, and Vice President and CMO at Suntory Pharmaceuticals. He earned both his MD and Ph.D., Pharmacology and Toxicology from the University of Medicine and Dentistry of New Jersey - New Jersey Medical School.

MannKind Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended of June 30, 2015

MannKind Corporation reported unaudited consolidated earnings results for the second quarter and six months ended of June 30, 2015. For the quarter, the company’s net loss was $28.9 million or $0.07 per share, narrowing from a net loss of $73.4 million or $0.19 per share. Loss from operations was $24,051,000 compared to $69,846,000 a year ago. Interest income was $3,000 compared to $1,000 a year ago. For the six months, the company reported loss from operations of $45,790,000 compared to $111,258,000 a year ago. Interest income was $6,000 compared to $2,000 a year ago. Net loss was $59,569,000 compared to $125,422,000 a year ago. Basic and diluted net loss per share was $0.15 compared to $0.33 a year ago.

MannKind Corp. to Report Q2, 2015 Results on Aug 10, 2015

MannKind Corp. announced that they will report Q2, 2015 results at 9:00 AM, US Eastern Standard Time on Aug 10, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNKD:US $3.80 USD +0.1499

MNKD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MNKD.
View Industry Companies

Industry Analysis


Industry Average

Valuation MNKD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MANNKIND CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at